Imke Bruns
- Naam
- I.B. Bruns
- ORCID iD
- 0000-0001-9681-6693
Voor meer informatie zie Engelse profielpagina.
- Di Tillio F., Wijaya L., Kunnen S., Eugenio C.J., Buzzanca G., Bruns I., Martens M., Kramer N., Kers J., Callegaro G., Water B. van de & Beltman J.B. (2026), Quantitative adverse outcome pathway modeling of cisplatin-induced nephrotoxicity: developing in vitro and in vivo models for predictive extrapolation, Toxicological Sciences 209(2): kfaf177.
- Di Tillio F., Wijaya L.S., Kunnen S.J., Eugenio J.C., Buzzanca G., Bruns I.B., Martens M., Kramer N.I., Kers J., Callegaro G., Water B. van de & Beltman J.B. (2026), Quantitative adverse outcome pathway modeling of cisplatin-induced nephrotoxicity: developing in vitro and in vivo models for predictive extrapolation, Toxicological Sciences 209(2): kfaf177.
- du Long R., Florquin M.S.N.C., Bemelman F.J., Claessen N., Varin A., Lamarthée B., Water B. van de, Bruns I.B., Callegaro G., Baelde H.J., Helm D. van der, Vries A.P.J. de, Peters-Sengers H., Florquin S. & Kers J. (2026), Clinicopathological and molecular characteristics of plasma cell-rich rejection in renal transplant biopsies, Transplantation : .
- Bruns I.B., Li Y., Stevens J.L., Water B. van de & Callegaro G. (2025), Cell type heterogeneity in gene co-expression networks: implications for toxicological research, Briefings in Bioinformatics 26(4): bbaf421.
- Bruns I.B. & Beltman J.B. (2022), Quantifying the contribution of transcription factor activity, mutations and microRNAs to CD274 expression in cancer patients, Scientific Reports 12(1): 4374.